Advisors Asset Management Inc. lessened its holdings in Celgene Co. (NASDAQ:CELG) by 81.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,896 shares of the biopharmaceutical company’s stock after selling 47,038 shares during the period. Advisors Asset Management Inc.’s holdings in Celgene were worth $3,321,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in CELG. Edgewood Management LLC grew its position in Celgene by 16.2% in the second quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company’s stock valued at $1,105,887,000 after acquiring an additional 1,943,607 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Celgene by 60.6% during the second quarter. Renaissance Technologies LLC now owns 4,129,438 shares of the biopharmaceutical company’s stock worth $327,960,000 after purchasing an additional 1,558,600 shares during the last quarter. Old Mutual Global Investors UK Ltd. grew its holdings in shares of Celgene by 4,047.3% during the first quarter. Old Mutual Global Investors UK Ltd. now owns 1,576,831 shares of the biopharmaceutical company’s stock worth $140,669,000 after purchasing an additional 1,538,810 shares during the last quarter. Natixis grew its holdings in shares of Celgene by 245.6% during the first quarter. Natixis now owns 1,746,416 shares of the biopharmaceutical company’s stock worth $155,798,000 after purchasing an additional 1,241,120 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Celgene by 14.8% during the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock worth $648,067,000 after purchasing an additional 1,051,528 shares during the last quarter. Hedge funds and other institutional investors own 73.07% of the company’s stock.
In other Celgene news, Director John H. Weiland purchased 5,575 shares of the company’s stock in a transaction on Tuesday, August 7th. The shares were purchased at an average cost of $89.73 per share, with a total value of $500,244.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ernest Mario sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total value of $1,107,840.00. Following the completion of the transaction, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.05. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.70 billion. Celgene had a return on equity of 87.28% and a net margin of 19.81%. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.82 earnings per share. equities analysts predict that Celgene Co. will post 7.64 earnings per share for the current fiscal year.
Several research firms have recently weighed in on CELG. Standpoint Research upgraded Celgene from a “hold” rating to a “buy” rating in a report on Monday, June 18th. BidaskClub cut Celgene from a “buy” rating to a “hold” rating in a report on Thursday, September 13th. Morgan Stanley boosted their price target on Celgene from $90.00 to $91.00 and gave the stock an “equal weight” rating in a report on Friday, July 13th. SunTrust Banks restated a “hold” rating and set a $101.00 price target on shares of Celgene in a report on Friday, July 27th. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 price target on the stock in a report on Wednesday, August 1st. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $121.85.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.